{"id":"NCT01421147","sponsor":"Eli Lilly and Company","briefTitle":"A Study in Adults With Type 1 Diabetes","officialTitle":"A Prospective, Randomized, Open-label Comparison of a Long-Acting Basal Insulin Analog LY2963016 to Lantus in Combination With Mealtime Insulin Lispro in Adult Patients With Type 1 Diabetes Mellitus","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-08","primaryCompletion":"2012-08","completion":"2013-04","firstPosted":"2011-08-22","resultsPosted":"2014-10-09","lastUpdate":"2014-10-09"},"enrollment":536,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Mellitus, Type 1"],"interventions":[{"type":"DRUG","name":"LY2963016","otherNames":[]},{"type":"DRUG","name":"Lantus","otherNames":[]},{"type":"DRUG","name":"Insulin Lispro","otherNames":[]}],"arms":[{"label":"LY2963016 + Insulin Lispro","type":"EXPERIMENTAL"},{"label":"Lantus + Insulin Lispro","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to compare the effectiveness and safety of LY2963016 versus Lantus when taken once daily in combination with insulin lispro before meals three times a day.","primaryOutcome":{"measure":"Change From Baseline up to 24 Weeks in Hemoglobin A1c (HbA1c)","timeFrame":"Baseline, Endpoint (up to 24 weeks)","effectByArm":[{"arm":"LY2963016 + Insulin Lispro","deltaMin":-0.352,"sd":0.053},{"arm":"Lantus + Insulin Lispro","deltaMin":-0.46,"sd":0.054}],"pValues":[{"comp":"OG000 vs OG001","p":"0.055"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":52,"countries":["United States","Belgium","Germany","Greece","Hungary","Japan","Mexico","Poland","Romania"]},"refs":{"pmids":["29855972"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":20,"n":268},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Diarrhoea","Back pain","Gastroenteritis"]}}